We found for
Supporting the Era of Green Pharmaceuticals in the UK
Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers
Payment Models for Multi-Indication Therapies
Payment Models for Multi-Indication TherapiesRead more
© Photology1971/Shutterstock
The Lower Drug Costs Now Act and Pharmaceutical Innovation
Opportunities to Increase Efficiency in Healthcare
Delivering the 2.4 Percent: Unlocking UK Pharma R&D Investment through Evidence-Based Policies
Unrelieved Pain in Palliative Care in England
